Gefitinib: 7 agencies, 2008–2015
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 7.2 years, from 23 Oct 2008 at AWMSG (Wales) to 7 Dec 2015 at SMC (Scotland).
SMC (Scotland) changed its position: not recommended on 10 May 2010, restricted by 7 Dec 2015, after a resubmission.
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2015; on this evidence the file is dormant.
5 distinct indication wordings are recorded for gefitinib by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess gefitinib, on 23 Oct 2008; CONITEC (Brazil) did not open a file until 8 Nov 2013 — a wide spread of 5.1 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 6 years in total.
4 of the 7 agencies here assessed gefitinib more than once, SMC (Scotland) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for gefitinib.
The full ledger for gefitinib reads 5 recommended, 2 not recommended, 2 deferred to NICE and 1 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 7 Dec 2015 | the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor tyros… | accepted (restricted) | source |
| HAS (France) | 23 Sep 2015 | Listing renewal (Transparency Committee) | SMR substantial | source |
| CONITEC (Brazil) | 8 Nov 2013 | Tratamento do câncer de pulmão de células Não pequenas avançado ou metastático com mutação EGFR, em primeira linha | incorporated into SUS | source |
| NICE (England) | 28 Jul 2010 | NICE TA192 | recommended | source |
| PHARMAC (New Zealand) | 7 May 2009 | Non-Small Cell Lung Cancer (NSCLC). second-line, locally advanced or metastatic | PTAC advice: Decline · decision reached | source |
6 further decisions for gefitinib, across 5 agencies, are not shown here. They link to 5 further source documents.
Related molecules
- ramucirumab — divergent outcome (recommended vs not recommended) on a shared indication
- mobocertinib — divergent outcome (recommended vs withdrawn) on a shared indication
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
Coverage: 11 decisions for gefitinib from 7 agencies, 2008 to 2015. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.